About HUYABIO International

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective, and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, including Shanghai, Beijing, Suzhou, Guangzhou and Wuhan, HUYABIO has become a partner of choice to accelerate product development and maximize value globally.

關(guān)于滬亞生物國(guó)際

滬亞生物是推進(jìn)中國(guó)原創(chuàng)生物醫(yī)藥進(jìn)行全球化共同開(kāi)發(fā)的企業(yè)，能以較快的速度、更經(jīng)濟(jì)的成本和較低的風(fēng)險(xiǎn)在全球市場(chǎng)進(jìn)行藥物開(kāi)發(fā)。通過(guò)與中國(guó)醫(yī)藥領(lǐng)域產(chǎn)、學(xué)、商各界的精誠(chéng)合作，滬亞生物建立了涵蓋全治療領(lǐng)域的中國(guó)原創(chuàng)化合物資源組合。公司在美國(guó)、日本、韓國(guó)、 加拿大、愛(ài)爾蘭、以及中國(guó)的戰(zhàn)略區(qū)域包括上海、北京、蘇州、廣州和武漢都設(shè)有辦事處。滬亞生物已成為加速產(chǎn)品開(kāi)發(fā)并在全球范圍實(shí)現(xiàn)產(chǎn)品價(jià)值最大化的合作伙伴。